pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
In the newest episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock speaks with Dr Colin Banas, chief medical officer at DrFirst.
They discuss out of control drug pricing, especially in the United States, that has led to nonadherence and care rationing
In the latest episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock speaks with Miruna Sasu, chief strategy officer of COTA and long-time pharma vet - before joining COTA last year, she headed up J&J’s Clinical Trial Feasibility and Advanced Analytics Team and led the Digital Health and Innovation Team at Bristol Myers Squibb.
In the latest episode of the pharmaphorum podcast, Editor in Chief Jonah Comstock speaks with Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe).
Tune in to hear about the year ahead in digital health and life sciences, as well as the need for partnership and collaboration more broadly between the pharma and tech worlds. Goldsack reports on what she heard in the virtual events surrounding JP Morgan this year, and then puts some of those insights into context out of her own experience.
In the latest episode of the pharmaphorum podcast, Dr Paul Tunnah speaks to head of Patient Engagement at Syneos Health, Marie Emms, and Elligo Health Research vice president, strategic partnerships, Keith Fern.
Together they discuss the changing nature of clinical trials how COVID-19 impacted the sector, and the role technology is playing in supporting trial enrolment and retention.
This episode of the pharmaphorum podcast is the second in a limited series focused on patient engagement that’s being led clinician, consultant and patient advocate, Mark Duman.
In the first episode of the ELICIT podcast, a new series produced in partnership with Cerner Enviza, the guests discuss qualitative real-world evidence and a unique dementia project from Singapore.
Episode 45 of the pharmaphorum podcast heard from Dr Stuart Hill, how he’s seen the oncology landscape change and which of those he sees holding the most potential to improve patient outcomes.
In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals at Sandoz about the big issues in biosimilars.
This episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s being led by Mark Duman, a clinician, consultant and patient advocate.
Episode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at Bristol Myers Squibb, about the future of pharma commercialisation and communications.
Episode 41 of the pharmaphorum podcast heard from Amit Nastik about the impact of COVID-19 on pharma supply chains and how he and his team mitigated disruption to Novartis’ own operations.
As the world passes the year and a half mark of the COVID-19 pandemic, the evolving experience of the ‘new normal’ environment across the healthcare sector has brought huge changes to the way pharma engages healthcare professionals.
The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular focus on oncology.
In the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager in the UK and Ireland.
In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer at the clinical-stage biopharmaceutical company Organicell Regenerative Medicine.
